Insilico Medicine has identified ISM9528, an AI-designed compound targeting neuropathic and postsurgical pain through an undisclosed mechanism. Preclinical data show efficacy comparable to or exceeding pregabalin with favorable safety and brain penetration, positioning the candidate for clinical trials by 2027.
Key Points
- AI-optimized compound shows superior efficacy in neuropathic pain models versus standard treatments
- Oral bioavailability with strong blood-brain barrier penetration and favorable safety profile
- 31st preclinical candidate from AI pipeline; clinical trials targeted for 2027
Longevity Analysis
Chronic and postsurgical pain substantially impairs functional capacity, sleep quality, and stress response—all core drivers of accelerated aging. Effective pain management without the dependence liability and systemic side effects of opioids or the cognitive effects of some gabapentinoids addresses a significant gap in longevity optimization. The speed of AI-driven drug discovery—12 to 18 months from target identification to preclinical nomination—suggests a new paradigm for translating emerging pain biology into clinical tools, potentially expanding the range of interventions available to practitioners focused on maintaining tissue integrity and nervous system resilience across the lifespan.
Original published by Longevity.Technology.